CN102240289A - 含氟班色林多晶型物a的药物组合物 - Google Patents

含氟班色林多晶型物a的药物组合物 Download PDF

Info

Publication number
CN102240289A
CN102240289A CN201110122058XA CN201110122058A CN102240289A CN 102240289 A CN102240289 A CN 102240289A CN 201110122058X A CN201110122058X A CN 201110122058XA CN 201110122058 A CN201110122058 A CN 201110122058A CN 102240289 A CN102240289 A CN 102240289A
Authority
CN
China
Prior art keywords
label
weight
present
composition
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201110122058XA
Other languages
English (en)
Chinese (zh)
Inventor
托马斯.弗里德尔
吉多.B.E.拉特克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of CN102240289A publication Critical patent/CN102240289A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201110122058XA 2002-05-22 2003-05-19 含氟班色林多晶型物a的药物组合物 Pending CN102240289A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02011224 2002-05-22
EP02011224.9 2002-05-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA038117029A Division CN1655789A (zh) 2002-05-22 2003-05-19 新型含氟班色林多晶型物a的药物组合物

Publications (1)

Publication Number Publication Date
CN102240289A true CN102240289A (zh) 2011-11-16

Family

ID=29433081

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201110122058XA Pending CN102240289A (zh) 2002-05-22 2003-05-19 含氟班色林多晶型物a的药物组合物
CNA2007100014771A Pending CN101002780A (zh) 2002-05-22 2003-05-19 新型含氟班色林多晶型物a的药物组合物
CNA038117029A Pending CN1655789A (zh) 2002-05-22 2003-05-19 新型含氟班色林多晶型物a的药物组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CNA2007100014771A Pending CN101002780A (zh) 2002-05-22 2003-05-19 新型含氟班色林多晶型物a的药物组合物
CNA038117029A Pending CN1655789A (zh) 2002-05-22 2003-05-19 新型含氟班色林多晶型物a的药物组合物

Country Status (25)

Country Link
EP (1) EP1511489B1 (https=)
JP (1) JP3919788B2 (https=)
KR (1) KR101054237B1 (https=)
CN (3) CN102240289A (https=)
AT (1) ATE499939T1 (https=)
BR (1) BRPI0311189B8 (https=)
CA (1) CA2483597C (https=)
CY (1) CY1111470T1 (https=)
DE (1) DE60336225D1 (https=)
DK (1) DK1511489T3 (https=)
EA (1) EA007185B1 (https=)
EC (1) ECSP045493A (https=)
ES (1) ES2361994T3 (https=)
HR (1) HRP20041092B1 (https=)
IL (1) IL164440A0 (https=)
ME (1) MEP55308A (https=)
MX (1) MXPA04011487A (https=)
NO (1) NO329414B1 (https=)
NZ (1) NZ537253A (https=)
PL (1) PL211062B1 (https=)
RS (1) RS51718B (https=)
SI (1) SI1511489T1 (https=)
UA (1) UA80135C2 (https=)
WO (1) WO2003097058A1 (https=)
ZA (1) ZA200408151B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
US20060264511A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
US20060264512A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of sexual dysfunction due to medical conditions
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
EP2037927B1 (en) * 2006-06-30 2010-01-27 Boehringer Ingelheim International GmbH Flibanserin for the treatment of urinary incontinence and related diseases
JP5793828B2 (ja) 2006-08-14 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フリバンセリンの製剤及びその製造方法
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
KR20090045945A (ko) 2006-08-25 2009-05-08 베링거 인겔하임 인터내셔날 게엠베하 제어 방출 시스템 및 이의 제조방법
ATE524446T1 (de) 2006-12-20 2011-09-15 Boehringer Ingelheim Int Sulfatierte benzimidazolon-derivate mit gemischter serotonin-rezeptor-affinität
EP1955699A1 (en) * 2007-02-08 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Use of flibanserin for the treatment of insomnia
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
EP2090297A1 (en) * 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CN104926734B (zh) * 2015-07-07 2017-04-05 苏州立新制药有限公司 氟班色林的制备方法
CN108699007A (zh) * 2016-01-31 2018-10-23 孟晓明 氟班色林的新晶型及其制备方法及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
UA76767C2 (uk) * 2001-08-02 2006-09-15 Бідакем С.П.А. Стабільна поліморфна модифікація флібансерину, спосіб її промислового одержання та її застосування для одержання лікарських засобів
DE10138273A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung

Also Published As

Publication number Publication date
BR0311189A (pt) 2005-02-22
BRPI0311189B8 (pt) 2021-05-25
JP3919788B2 (ja) 2007-05-30
PL211062B1 (pl) 2012-04-30
ES2361994T3 (es) 2011-06-27
EA007185B1 (ru) 2006-08-25
UA80135C2 (en) 2007-08-27
SI1511489T1 (sl) 2011-06-30
IL164440A0 (en) 2005-12-18
JP2005530787A (ja) 2005-10-13
NZ537253A (en) 2007-09-28
KR20040111668A (ko) 2004-12-31
MEP55308A (en) 2011-05-10
EP1511489A1 (en) 2005-03-09
DK1511489T3 (da) 2011-05-02
KR101054237B1 (ko) 2011-08-08
PL372457A1 (en) 2005-07-25
EP1511489B1 (en) 2011-03-02
CN1655789A (zh) 2005-08-17
CN101002780A (zh) 2007-07-25
ECSP045493A (es) 2005-03-10
WO2003097058A1 (en) 2003-11-27
NO329414B1 (no) 2010-10-18
CA2483597A1 (en) 2003-11-27
NO20044547L (no) 2004-12-17
ATE499939T1 (de) 2011-03-15
HRP20041092A2 (en) 2005-06-30
AU2003240672A1 (en) 2003-12-02
RS98704A (sr) 2006-12-15
DE60336225D1 (de) 2011-04-14
CA2483597C (en) 2010-02-09
EA200401515A1 (ru) 2005-06-30
RS51718B (sr) 2011-10-31
ZA200408151B (en) 2006-06-28
BRPI0311189B1 (pt) 2019-04-09
MXPA04011487A (es) 2005-02-14
HRP20041092B1 (hr) 2013-05-31
CY1111470T1 (el) 2015-08-05

Similar Documents

Publication Publication Date Title
CN102240289A (zh) 含氟班色林多晶型物a的药物组合物
US20070196473A1 (en) Pharmaceutical compositions containing flibanserin
CN101005830B (zh) 包含普拉克索或其可药用盐的延长释放片剂、其制备方法及用途
JP5401327B2 (ja) 溶出性の改善された錠剤
EP3226843B1 (en) Anticancer compositions
RU2466717C2 (ru) Фармацевтический твердый препарат, содержащий бензоазепины, и способ его получения
CN101541326A (zh) 雌激素/选择性雌激素受体调节剂（serm）和雌激素/孕酮双层药片
TWI469802B (zh) Solid dispersion preparation
TW201735928A (zh) 溶出性優異之口服製劑
KR20050043765A (ko) 방출 제어형 메트포르민 정제
CN102292075B (zh) 包含hcv聚合酶抑制剂前药的药物组合物
CN108778281B (zh) 一种吡啶酮类衍生物药物组合物及其制备方法
AU2003267216A1 (en) Mannitol formulation for integrin receptor antagonist
AU2003240672B2 (en) New pharmaceutical compositions containing flibanserin polymorph A
JP5563371B2 (ja) クエチアピンフマル酸塩含有経口用錠剤
WO2023217694A1 (en) Pharmaceutical composition of bempedoic acid
HK1104975A (en) New pharmaceutical compositions containing flibanserin polymorph a
HK1261010A1 (en) Pyridone derivative pharmaceutical composition and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20111116